About
Laura Deming is a longevity-focused venture capitalist and founder of The Longevity Fund, an early-stage fund she started in 2011 to back companies working on aging and healthy lifespan extension. TechCrunch reports she attended MIT at 14, joined the Thiel Fellowship at 16, raised a $4 million first fund and then a $22 million second fund for The Longevity Fund. She is also CEO and co-founder of Until Labs and is associated with age1, the next-generation longevity investing platform that followed her AGE1 accelerator experiment.
Areas of interest
longevityaging biologybiotechhealthspan extensionage-related disease therapeuticsfounder-led biotechgene editingsenolyticsneurodegenerationorgan cryopreservationregenerative medicine